Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection

Microb Pathog. 2017 Sep:110:477-483. doi: 10.1016/j.micpath.2017.07.037. Epub 2017 Jul 25.

Abstract

Uropathogenic Escherichia coli (UPEC) are among the most prevalent agents of urinary tract infections (UTIs). Antibiotic resistance reaches the need for alternative treatment approaches such as vaccination against UTIs. There is no ideal vaccine against UTIs, thus there is a need to evaluate different targets of uropathogens against UTIs. Ferric scavenger receptor FyuA in UPEC has the properties of an ideal vaccine candidate against UTIs. In the present study, the prevalence of FyuA among UPEC isolates, its immunogenicity with and without alum adjuvant, and its efficacy against experimental UTI were assessed. Totally, fyuA gene was present in 77% of the UPEC isolates tested. Alignments of FyuA exhibited a high degree of conservation among different submitted UPEC isolates in GenBank. The bioinformatics studies showed the high confidence value and stability of the FyuA structure. SDS-PAGE and Western blot confirmed the purification of FyuA with high yield by nickel resins. Mice vaccinated subcutaneously with the FyuA induced a significantly higher humoral response (total IgG, IgG1 and IgG2a) than control mice that alum enhanced these responses. The FuyA alone showed the ability to reduce the colonization of UPEC in bladder and kidney of mice as compared to the control group. But the addition of alum to FyuA increased the protection level against UPEC in these organs. Since, FyuA induced significant IgG1 (Th2) and IgG2a (Th1) responses and protected the mice against experimental UTI, it could be a promising target against UPEC infections.

Keywords: Bioinformatics' studies; FyuA; Humoral response; Urinary tract infection; Uropathogenic E. coli; Vaccine candidate.

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Alum Compounds / administration & dosage
  • Animals
  • Antibodies, Bacterial / blood
  • Escherichia coli Infections / microbiology
  • Escherichia coli Infections / prevention & control*
  • Escherichia coli Proteins / genetics
  • Escherichia coli Proteins / immunology*
  • Escherichia coli Vaccines / administration & dosage
  • Escherichia coli Vaccines / immunology*
  • Immunoglobulin G / blood
  • Injections, Subcutaneous
  • Kidney / microbiology
  • Mice
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / immunology*
  • Treatment Outcome
  • Urinary Bladder / microbiology
  • Urinary Tract Infections / microbiology
  • Urinary Tract Infections / prevention & control*
  • Uropathogenic Escherichia coli / genetics
  • Uropathogenic Escherichia coli / immunology*

Substances

  • Adjuvants, Immunologic
  • Alum Compounds
  • Antibodies, Bacterial
  • Escherichia coli Proteins
  • Escherichia coli Vaccines
  • FyuA protein, E coli
  • Immunoglobulin G
  • Receptors, Cell Surface
  • aluminum sulfate